Related Experiment Videos
Thorotrast-associated liver cancer.
The American Journal of Gastroenterology
|September 1, 1985
Summary
Thorotrast-related liver cancer is a rare occurrence. This case highlights the long latency period between Thorotrast exposure and cancer development, emphasizing the need for lifelong patient monitoring.
Area of Science:
- Hepatology
- Oncology
- Radiology
Background:
- Thorotrast (colloidal solution of thorium dioxide) was historically used as an intravenous contrast agent.
- Its use ceased due to recognized long-term health risks, including carcinogenicity.
- This abstract details a rare case of liver cancer linked to past Thorotrast administration.
Observation:
- A patient developed liver cancer 38 years after receiving intravenous Thorotrast in 1947.
- The latency period underscores the delayed oncogenic effects of Thorotrast.
- This case represents an infrequent but significant clinical presentation.
Findings:
- The study presents a confirmed case of Thorotrast-related liver cancer.
- A review of historical literature on Thorotrast use and its associated hazards is included.
- The findings emphasize the carcinogenic potential of Thorotrast, particularly for liver malignancies.
Implications:
- Highlights the critical importance of identifying individuals with prior Thorotrast exposure.
- Underscores the necessity for long-term surveillance in Thorotrast carriers due to cancer risk.
- Informs clinical practice regarding the delayed risks associated with historical contrast agents.